Related trials
Gardecki, 3000 - Ticlopidine vs placebo
Lyon-II, 3000 - Ticlopidine vs placebo
ADVANCE 2, 2010 - apixaban vs enoxaparin (europe regimen)
ADVANCE 3, 2010 - apixaban vs enoxaparin
RECORD 4, 2009 - rivaroxaban vs enoxaparin (US regimen)
DRIVE, 2008 - SR123781A vs enoxaparin
RECORD 3, 2008 - rivaroxaban vs enoxaparin (europe regimen)
RE-MOBILIZE (150mg), 2008 - dabigatran 150mg vs enoxaparin (US regimen)
RECORD 2, 2008 - rivaroxaban (long duration) vs enoxaparin (short duration)
RE-MOBILIZE (220mg), 2008 - dabigatran 220mg vs enoxaparin (US regimen)
RECORD 1, 2008 - rivaroxaban vs enoxaparin
ADVANCE-1, 2008 - apixaban vs enoxaparin (US regimen)
RE-NOVATE (220mg), 2007 - dabigatran 220mg vs enoxaparin
Cohen (L8405), 2007 - compression stocking group vs control (on top fondaparinux)
RE-MODEL (220mg), 2007 - dabigatran 220mg vs enoxaparin (europe regimen)
RE-NOVATE (150mg), 2007 - dabigatran 150mg vs enoxaparin
APROPOS 2.5mg, 2007 - apixaban vs enoxaparin (US regimen)
RE-MODEL (150mg), 2007 - dabigatran 150mg vs enoxaparin (europe regimen)
ODIXa-HIP 10mg, 2006 - rivaroxaban vs enoxaparin (short duration)
ODIXa-KNEE, 2005 - rivaroxaban vs enoxaparin (US regimen)
EXPRESS, 2003 - ximelagatran vs Enoxaparin
Platinum (Colwell), 2003 - ximelagatran vs Enoxaparin
PENTHIFRA�PLUS (Eriksson), 2003 - extended prophylaxis vs standard prophylaxis
PENTATHLON (Turpie), 2002 - fondaparinux vs enoxaparin
METHRO III, 2002 - ximelagatran vs Enoxaparin
See also:
All DVT prophylaxis clinical trials
All clinical trials of antithrombotics
All clinical trials of Acenocoumarol
|
|
Treatments
Studied treatment |
Acenocoumarol
|
Control treatment |
Nadroparin 60 anti-Xa IU /kg x1
|
Patients
Patients |
THR or TKR (stratified) |
Method and design
Randomized effectives |
342 / 330 (studied vs. control) |
Blinding |
single blind |
Follow-up duration |
Day 10 � 2 |
Results
Endpoint
Studied treat. n/N
Control treat. n/N
Graph
RR [95% CI]
Deep vein thrombosis
50 / 257
43 / 260
1,18 [0,81;1,70]
Symptomatic pulmonary embolism
0 / 342
0 / 330
classic
0,96 [0,00;246,15]
proximal DVT
15 / 257
17 / 260
0,89 [0,46;1,75]
Major bleeding
0
2
1.0
Relative risks
|
Endpoint |
Events (%) |
Relative Risk |
95% CI |
Endpoint definition in the trial |
Ref |
Studied treat. |
Control treat. |
Deep vein thrombosis
|
50 / 257 (19,5%) |
43 / 260 (16,5%) |
1,18 |
[0,81;1,70] |
|
|
Symptomatic pulmonary embolism
|
0 / 342 (0,1%) |
0 / 330 (0,2%) |
0,96 |
[0,02;48,49] |
|
|
proximal DVT
|
15 / 257 (5,8%) |
17 / 260 (6,5%) |
0,89 |
[0,46;1,75] |
|
|
The primary endpoint (if exists) appears in blod characters
|
Reference(s) used for data extraction:
|
Endpoint |
studied treat. |
control treat. |
mean diff |
Absolute risk reduction
|
Endpoint |
Events rate |
Absolute risk reduction (ARR) |
Studied treat. |
Control treat. |
Deep vein thrombosis |
19,46% |
16,54% |
2,9%
|
proximal DVT |
5,84% |
6,54% |
-7,0‰
|
Meta-analysis of all similar trials:
anticoagulant in DVT prophylaxis for orthopedic surgery
antithrombotics in DVT prophylaxis for orthopedic surgery
Reference(s)
-
Hamuly�k K, Lensing AW, van der Meer J, Smid WM, van Ooy A, Hoek JA.
Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group..
Thromb Haemost 1995;74:1428-31
Pubmed
|
Hubmed
| Fulltext
|